Patent intelligence · US
US 10729651
Sustained release formulation of a non-steroidal anti-inflammatory drug
Sustained release formulation of a non-steroidal anti-inflammatory drug
Patent details — US 10729651
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 4, 2020
- Expiration
- Jul 30, 2040
- Applicant
- Pacira Pharmaceuticals, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/196, A61K31/407, A61K31/5415
Quick answer
US 10729651 (Sustained release formulation of a non-steroidal anti-inflammatory drug) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Aug 4, 2020. Expires Jul 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Pacira Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/196, A61K31/407, A61K31/5415, A61K9/127, A61K9/1272
More from Pacira Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12370142
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12364764
Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same
granted -
US 12318483
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12296047
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12285435
Multivesicular liposome formulations of dexamethasone
granted -
US 12285419
Bupivacaine multivesicular liposome formulations and uses thereof
granted -
US 12280149
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12251472
Manufacturing of bupivacaine multivesicular liposomes
granted
Frequently asked questions
What is US patent 10729651?
US 10729651 (Sustained release formulation of a non-steroidal anti-inflammatory drug) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Aug 4, 2020. Expires Jul 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10729651?
Pacira Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 10729651 expire?
Our index shows an expiration date of Jul 30, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.